Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

German (DAX) Clinical Research and Equipment Industry Analysis

UpdatedMar 23, 2026
DataAggregated Company Financials
Companies6
  • 7D-0.7%
  • 3M-16.1%
  • 1Y-25.5%
  • YTDn/a

The Clinical Research and Equipment is pretty flat in the last 7 days, but Gerresheimer has stood out, gaining 22%. As for the longer term, the industry has declined 25% in the last year. Earnings are forecast to grow by 22% annually.

Industry Valuation and Performance

Has the German Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 23 Mar 2026€16.3b€7.5b€168.6m32x96.6x2.2x
Wed, 18 Feb 2026€18.2b€7.5b€168.3m31.2x108.1x2.4x
Fri, 16 Jan 2026€20.2b€7.5b€143.5m38.8x140.8x2.7x
Sun, 14 Dec 2025€19.1b€7.5b€143.5m41.5x132.9x2.5x
Tue, 11 Nov 2025€18.3b€7.5b€143.9m35.3x127.1x2.4x
Thu, 09 Oct 2025€19.3b€7.4b€157.8m21.1x122.1x2.6x
Sat, 06 Sep 2025€17.9b€7.4b€157.8m22.5x113.3x2.4x
Mon, 04 Aug 2025€17.7b€7.4b€107.0m24.1x165.5x2.4x
Wed, 02 Jul 2025€20.8b€7.3b€114.9m29x180.9x2.8x
Fri, 30 May 2025€21.2b€7.3b€114.9m28.7x184.4x2.9x
Sun, 27 Apr 2025€21.1b€7.3b€112.4m26.6x187.5x2.9x
Tue, 25 Mar 2025€21.8b€7.1b€156.5m26.5x139.2x3x
Thu, 20 Feb 2025€22.8b€7.1b€161.1m26.7x141.8x3.2x
Sat, 18 Jan 2025€21.8b€7.1b€169.8m24.7x128.6x3.1x
Mon, 16 Dec 2024€21.9b€7.1b€169.8m24.1x128.8x3.1x
Wed, 13 Nov 2024€22.7b€7.1b€170.5m28.4x133.2x3.2x
Fri, 11 Oct 2024€22.7b€7.1b€177.5m29x127.8x3.2x
Sun, 08 Sep 2024€24.4b€7.1b€172.8m34x141.4x3.5x
Tue, 06 Aug 2024€24.5b€7.0b€237.1m36x103.2x3.5x
Thu, 04 Jul 2024€23.5b€7.0b€309.8m33.9x75.9x3.4x
Sat, 01 Jun 2024€24.6b€7.0b€333.3m31x73.9x3.5x
Mon, 29 Apr 2024€29.0b€7.0b€340.1m37.9x85.2x4.1x
Wed, 27 Mar 2024€34.3b€7.1b€384.5m37.7x89.1x4.8x
Fri, 23 Feb 2024€33.0b€7.1b€369.5m37.7x89.3x4.7x
Sun, 21 Jan 2024€28.7b€7.3b€507.1m33.6x56.6x3.9x
Tue, 19 Dec 2023€32.6b€7.3b€507.1m34x64.2x4.5x
Thu, 16 Nov 2023€27.4b€7.3b€507.1m29.4x54x3.8x
Sat, 14 Oct 2023€24.0b€6.6b€498.8m35.9x48x3.6x
Mon, 11 Sep 2023€29.1b€6.6b€498.1m42.2x58.5x4.4x
Wed, 09 Aug 2023€29.3b€6.6b€425.8m42.4x68.8x4.5x
Fri, 07 Jul 2023€26.4b€6.8b€496.6m35.5x53.2x3.9x
Sun, 04 Jun 2023€28.2b€6.7b€487.3m39.1x57.8x4.2x
Tue, 02 May 2023€28.0b€6.7b€483.0m38.8x58x4.2x
Thu, 30 Mar 2023€31.0b€6.7b€594.3m35.2x52.1x4.6x
Price to Earnings Ratio

52.1x


Total Market Cap: €31.0bTotal Earnings: €594.3mTotal Revenue: €6.7bTotal Market Cap vs Earnings and Revenue0%0%0%
German Clinical Research and Equipment Industry Price to Earnings3Y Average 107.6x202420252026
Current Industry PE
  • Investors are pessimistic on the German Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 96.6x which is lower than its 3-year average PE of 108x.
  • The 3-year average PS ratio of 3.4x is higher than the industry's current PS ratio of 2.2x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have declined 34% per year over the last three years.
  • Meanwhile revenues for these companies have grown 4.1% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does German Clinical Research and Equipment compare with similar industries?

DE Market-4.00%
Healthcare-4.29%
Life Sciences-0.67%
Clinical Research and Equipment-0.67%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GXI Gerresheimer€21.6019.0%
+€119.2m		-71.5%PE32x
EVT Evotec€4.300.8%
+€5.9m		-35.2%PS1x

Latest News

GXI
€21.60
Gerresheimer
7D
19.0%
1Y
-71.5%

GXI: FY25 Warning And Deferred Results Will Pressure Shares Further

Analysts have reduced their price target for Gerresheimer to about €12.50 from around €18.90, citing lower short- and mid-term estimates following the recent FY25 warning and expectations that FY26 outcomes could sit near the low end of company guidance. Analyst Commentary Bearish analysts are signaling a more cautious view on Gerresheimer following the recent FY25 warning, with fresh price targets pointing to a more conservative stance on both earnings power and execution over the next few years.
EVT
€4.30
Evotec
7D
0.8%
1Y
-35.2%

EVT: Earnings Outlook Will Balance Higher Guidance With Tighter Profit Assumptions

Analysts have reduced their Evotec price targets from €6.00 to €4.40 as they apply a higher discount rate, assume slower revenue growth and lower profit margins, and factor in a slightly higher future P/E of 24.33x. What's in the News Evotec raised its full-year 2025 earnings guidance, now expecting group revenues of approximately €788 million at the high end of its €760 to €800 million range, or €811 million at constant exchange rates (Key Developments) The company confirmed new earnings guidance for full-year 2026, with group revenues expected in a range of approximately €700 to €780 million, or €730 to €810 million at constant exchange rates (Key Developments) Valuation Changes Fair Value: reduced from €6.00 to €4.40 per share, reflecting a lower implied valuation level.
1SXP
€12.96
SCHOTT Pharma KGaA
7D
-3.9%
1Y
-45.1%

1SXP: Dividend And 2026 Guidance Will Support Confidence In Undervalued Shares

Analysts have maintained the price target for SCHOTT Pharma KGaA at €25.90. They cited only minor adjustments to inputs such as the discount rate, revenue growth assumptions, profit margin, and future P/E, which did not materially affect their overall valuation view.